Xie, Lifang
Ng, Ding Quan
Heshmatipour, Matthew
Acharya, Munjal
Coluzzi, Paul
Guerrero, Nerida
Lee, Sanghoon
Malik, Shaista
Parajuli, Ritesh
Stark, Craig
Tain, Rongwen
Zabokrtsky, Keri
Torno, Lilibeth
Chan, Alexandre
Article History
Received: 2 March 2023
Accepted: 17 March 2023
First Online: 27 March 2023
Declarations
:
: Our trial has been approved by the UCI IRB (IRB #20216732). We foresee the study will be completed in the first quarter of 2024.
: All aspects of this study abide by the ethical guidelines put in place by the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report. All participants involved in this study will be made aware of the potential risks and harms of this study and will be screened to ensure they are able to give consent. They will be made aware of any potential direct benefits and reminded of the three principles underlying the ethical conduct of research: Respect for persons, Beneficence, and Justice. The study was approved by the UC Irvine Institutional Review Board on September 12, 2022 (Reviewed by Farshid Dayyani, MD, PhD UCI IRB #20216732).
: Not applicable.
: The authors declare that they have no competing interests.